Company research
NEXGEL, INC.
CIK 1468929Updated Sep 24, 2026
Name history
NEXGEL, INC. · through Sep 23, 2026AquaMed Technologies, Inc. · through Nov 14, 2019
NXGL price & chart
Loading TradingView…
NASDAQ:NXGL on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
DEF 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
S-1 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,461,000Source | 10,983,000Source | 9,955,000Source | 10,357,000Source |
| Property, Plant and Equipment, NetUSD | 1,955,000Source | 2,211,000Source | 1,499,000Source | 721,000Source |
| GoodwillUSD | 1,128,000Source | 1,128,000Source | 1,128,000Source | 311,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 681,000Source | 807,000Source | 326,000Source | 20,000Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 673,000Source | 933,000Source | 633,000Source | 222,000Source |
| Inventory, NetUSD | 2,111,000Source | 1,751,000Source | 1,319,000Source | 502,000Source |
| Assets, CurrentUSD | 4,338,000Source | 5,114,000Source | 5,052,000Source | 7,505,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 496,000Source | 623,000Source | 400,000Source | 172,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,015,000Source | 1,628,000Source | 1,855,000Source | 1,737,000Source |
| Other Assets, NoncurrentUSD | 95,000Source | 95,000Source | 95,000Source | 63,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,570,000Source | 4,903,000Source | 4,789,000Source | 2,720,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8,000Source | 8,000Source | 6,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 25,447,000Source | 23,743,000Source | 19,406,000Source | 19,189,000Source |
| Retained Earnings (Accumulated Deficit)USD | -20,996,000Source | -17,996,000Source | -14,715,000Source | -11,558,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,459,000Source | 5,755,000Source | 4,697,000Source | 7,637,000Source |
| Liabilities and EquityUSD | 10,461,000Source | 10,983,000Source | 9,955,000Source | 10,357,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,956,000Source | 2,470,000Source | 2,549,000Source | 859,000Source |
| Operating Lease, Liability, CurrentUSD | 310,000Source | 237,000Source | 233,000Source | 207,000Source |
| Accounts Payable, CurrentUSD | — | — | 1,233,000Source | 265,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,883,000Source | 1,538,000Source | 1,727,000Source | 1,593,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 432,000Source | 325,000Source | 469,000Source | — |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 2,000Source | 179,000Source | — | — |
| Long-term DebtUSD | 588,000Source | 685,000Source | 593,000Source | 283,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -2,893,000Source | -3,463,000Source | -3,188,000Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 450,000Source | 436,000Source | 226,000Source | 112,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 654,000Source | 367,000Source | 217,000Source | 298,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -260,000Source | 300,000Source | 411,000Source | 13,000Source |
| Increase (Decrease) in InventoriesUSD | 360,000Source | 432,000Source | 760,000Source | 211,000Source |
| Increase (Decrease) in Accounts PayableUSD | -38,000Source | 182,000Source | 968,000Source | 11,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,311,000Source | -3,867,000Source | -3,236,000Source | -2,992,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 500,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -68,000Source | -775,000Source | 4,456,000Source | -5,595,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 68,000Source | 443,000Source | 696,000Source | 96,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 630,000Source | 3,749,000Source | 379,000Source | -3,662,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 89,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | 1,324,000Source |
| Amortization of Intangible AssetsUSD | 126,000Source | 119,000Source | 94,000Source | — |
| DepreciationUSD | 324,000Source | 319,000Source | 132,000Source | 99,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | -150,000Source |
| GoodwillUSD | 1,128,000Source | 1,128,000Source | 1,128,000Source | 311,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| InterestExpenseNonoperatingUSD | 34,000Source | 81,000Source | — | — |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | 68,000Source | 191,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | 68,000Source | 191,000Source | 9,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 9,000Source |
| Net Income (Loss) Attributable to ParentUSD | -3,000,000Source | -3,281,000Source | -3,157,000Source | -4,746,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 107,000Source | -182,000Source | -31,000Source | — |
| Nonoperating Income (Expense)USD | 459,000Source | 91,000Source | 289,000Source | -1,398,000Source |
| Operating ExpensesUSD | 7,861,000Source | 6,302,000Source | 4,096,000Source | 3,604,000Source |
| Operating Lease, ExpenseUSD | 314,000Source | 287,000Source | 303,000Source | 246,000Source |
| Proceeds from Noncontrolling InterestsUSD | — | 38,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 11,421,000Source | 8,688,000Source | 4,089,000Source | 2,048,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 11,421,000Source | 8,688,000Source | 4,089,000Source | 2,048,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 7,859,000Source | 6,224,000Source | 3,993,000Source | 3,237,000Source |
| Operating Income (Loss)USD | -3,352,000Source | -3,554,000Source | -3,477,000Source | -3,348,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -2,893,000Source | -3,463,000Source | -3,188,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 107,000Source | -182,000Source | -31,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -3,000,000Source | -3,281,000Source | -3,157,000Source | -4,746,000Source |
| Earnings Per Share, BasicUSD per share | -0.38Source | -0.5Source | -0.56Source | -0.85Source |
| Earnings Per Share, DilutedUSD per share | -0.38Source | -0.5Source | -0.56Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 7,854,288Source | 6,511,574Source | 5,671,842Source | 5,574,818Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 7,854,288Source | 6,511,574Source | 5,671,842Source | — |
| Interest Expense (non-operating)USD | 34,000Source | 81,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 126,000Source | 119,000Source | 94,000Source | — |
| Gross ProfitUSD | 4,509,000Source | 2,748,000Source | 619,000Source | 256,000Source |
| Interest ExpenseUSD | — | — | 15,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | 68,000Source | 191,000Source | 9,000Source |
| Nonoperating Income (Expense)USD | 459,000Source | 91,000Source | 289,000Source | -1,398,000Source |
| Operating ExpensesUSD | 7,861,000Source | 6,302,000Source | 4,096,000Source | 3,604,000Source |
| Operating Lease, ExpenseUSD | 314,000Source | 287,000Source | 303,000Source | 246,000Source |
| Research and Development ExpenseUSD | 2,000Source | 78,000Source | 103,000Source | 367,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 11,421,000Source | 8,688,000Source | 4,089,000Source | 2,048,000Source |
Offerings
Registration 333-298449
Filing attachments
ex99-1.htm · 8-K · 2026-08-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE LANGHORNE, Pa. - August 20, 2026 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”) today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve liquidity, and enhance long-term shareholder value. The actions include the appointment of Brian Kieser as Interim Chief Executive Officer and the formation…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NEXGEL Reports Second Quarter 2026 Financial Results LANGHORNE, Pa. - August 17, 2026 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2026 financial results for the period ending June 30, 2026. The second quarter of 2026 w…
Read attachment ↗ex4-1.htm · 8-K · 2026-05-15
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN…
Read attachment ↗ex4-2.htm · 8-K · 2026-05-15
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILA…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa. - May 6, 2026 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hyd…
Read attachment ↗